Tg Therapeutics: RSI Overbought, Bollinger Bands Narrowing on 15-Minute Chart

Tg Therapeutics's 15-minute chart has triggered an RSI overbought signal and Bollinger Bands narrowing at 09/03/2025 15:45, indicating that the stock price has risen too quickly and is above its fundamental support level. Furthermore, the magnitude of the stock price fluctuations has decreased, suggesting a potential reversal in the trend.

At 15:45 on September 3, 2025, the 15-minute chart of Tg Therapeutics (TGTX) triggered an RSI overbought signal and a narrowing of Bollinger Bands, indicating a potential reversal in the stock's upward trend. This technical analysis suggests that the stock price has risen too quickly and is above its fundamental support level. Additionally, the decreased magnitude of price fluctuations points to a possible trend reversal.

RSI Overbought Signal

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. An RSI over 70 is generally considered overbought, indicating that the stock may be overvalued and due for a correction. On September 3, 2025, the RSI for Tg Therapeutics (TGTX) surpassed 70, signaling that the stock price has risen too quickly and may be due for a pullback.

Narrowing Bollinger Bands

Bollinger Bands are volatility indicators that consist of a simple moving average and two standard deviations above and below it. When the bands narrow, it indicates that the price volatility is decreasing. This narrowing of Bollinger Bands on September 3, 2025, suggests that the stock price fluctuations have decreased, which can be a sign of a trend reversal or consolidation.

Implications for Investors

Investors should be cautious and monitor the stock closely for any further signals that could indicate a trend reversal. The overbought RSI and narrowing Bollinger Bands suggest that the stock may be due for a correction, but it is essential to wait for additional confirmation before making any trading decisions.

Recent News and Events

TG Therapeutics (TGTX) has been actively participating in various conferences and reporting strong financial results. On August 4, 2025, the company reported its second quarter 2025 financial results, with total revenue reaching $141.1 million, primarily driven by BRIUMVI U.S. net revenue of $138.8 million, representing a 91% year-over-year growth and a 16% growth over Q1 2025. The company also raised its full-year 2025 revenue guidance and reported a strong cash position of $278.9 million [3].

Conclusion

The recent technical analysis signals for Tg Therapeutics (TGTX) indicate a potential trend reversal. Investors should be vigilant and monitor the stock closely for further confirmation. The company's strong financial performance and active participation in industry events suggest a promising outlook, but the current technical signals warrant caution.

References

[1] https://www.stocktitan.net/news/TGTX/
[2] https://www.stocktitan.net/news/TGTX/
[3] https://www.stocktitan.net/news/TGTX/